Stock CTMX CYTOMX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Real-time Estimate Cboe BZX
Other stock markets
 11:48:25 2024-04-18 am EDT 		5-day change 1st Jan Change
1.765 USD +0.28% Intraday chart for CytomX Therapeutics, Inc. -18.04% +13.69%
Apr. 08 CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors CI
Mar. 21 CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CytomX Therapeutics : 2023 Annual Report
PU
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
AQ
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors
CI
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
AQ
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
AQ
CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors
CI
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
AQ
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas
CI
Transcript : CytomX Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating
MT
North American Morning Briefing : Inflation Data Back in the Spotlight
DJ
Stocks to Watch : Oracle, Mission Produce, CytomX Therapeutics
DJ
CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate
DJ
Transcript : CytomX Therapeutics, Inc., Q4 2023 Earnings Call, Mar 11, 2024
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q4 Revenue $26.6M, vs. Street Est of $21.2M
MT
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
AQ
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
AQ
CytomX Therapeutics to Present at Upcoming March Investor Conferences
AQ
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTMX Stock
  4. News CytomX Therapeutics, Inc.